AlphaMedix

Phase 2Small molecule

OOrano Med LLC

AlphaMedix is one of 4 small molecule programs targeting Neuroendocrine Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine TumorActive, not recruiting

Neuroendocrine TumorPhase 2

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Neuroendocrine Tumor

#DrugCompanyPhaseTrials

Lutathera

AAdvanced Accelerator Applications

Approved

1 2

Votrient

Novartis

Phase 2

1 3

Recombinant Human GM-CSF

EEastern Cooperative Oncology Group

Phase 3

1 4

AlphaMedix

OOrano Med LLC

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Active, not recruiting

Neuroendocrine Tumor

NCT05153772

Clinical

Trials by Indication[1]

Adult Subject1 trial

Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET

Terminated·OOrano Med LLC·Phase 1·NCT03466216·33 enrolled

Neuroendocrine Tumor1 trial

Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients

Active, not recruiting·OOrano Med LLC·Phase 2·NCT05153772·69 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AlphaMedix. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AlphaMedix compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AlphaMedix. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Orano Med LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: OOrano Med LLC

AlphaMedix

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Adult Subject1 trial

Neuroendocrine Tumor1 trial

References

Drug Info

Quick Facts

Related News